Pharmaceutical Drugs Industry Overview

CAR-T Therapy Market Definition

The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of pharmaceutical quality, safety, and efficacy, and are used to boost immunity by identifying and neutralizing foreign bodies. The market consists of revenue generated by the biosimilar monoclonal antibodies companies by the sales of these products. The global biosimilar monoclonal antibodies market is expected to grow from $3.48 billion in 2019 to $3.62 billion in 2020 at a compound annual growth rate (CAGR) of 3.93%. The slow growth rate is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The market is then expected to recover and reach $7.93 billion in 2023 at a CAGR of 29.91%. North America was the largest region in the biosimilar monoclonal antibodies market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune disease, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. According to the American Cancer Society (ACS), in 2020, about 1.8 million new cancer cases and 0.6 million cancer deaths are expected to take place in the United States. Therefore, the prevalence of chronic diseases including cancer is expected to drive the biosimilar monoclonal antibodies market. Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the biosimilar monoclonal antibodies market. The governments of different regions impose different rules regarding the production and use of biosimilars. Additionally, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars including 4 originating from biologics could enter the US commercial market. The robust government policies for approval of these drugs negatively impact manufacturers in the biosimilar monoclonal antibodies market. The focus area for many companies in the biosimilar monoclonal antibodies market has shifted towards mergers and acquisitions to acquire more production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets. In February 2017, Aurobindo Pharma Limited announced that it had acquired four cell culture-derived biosimilar products from TL Biopharmaceutical AG of Switzerland. As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally. Out of the four biosimilars acquired, three of them are monoclonal antibodies in oncology. In another instance, in May 2020, AbbVie, a US-based biopharmaceutical company, announced its decision to acquire Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie`s revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies. In May 2020, AbbVie, a US-based biopharmaceutical company, has acquired Allergan for an amount of $63 million. This transaction expands and diversifies AbbVie`s revenue base and supports in maintaining its leadership positions in biosimilar monoclonal antibodies. Allergan also provides new growth opportunities in the neuroscience field, with Botox Therapeutics, Vraylar, and Ubrelvy. Allergan is an Ireland-based pharmaceutical company that manufactures, develops, and markets drugs, biosimilars, medical devices, eye care, and others. The global biosimilar monoclonal antibodies market is segmented - 1) By Type: Synthetic Chemicals, Biopharmaceuticals, Others. 2) By Application: Chronic & Autoimmune Diseases, Oncology, Others.

The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson`s disease (PD), generated by the establishments that manufacture these drugs. Parkinson`s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems. The global anti-Parkinson drugs market is expected to decline from $4.23 billion in 2019 to $4.12 billion in 2020 at a compound annual growth rate (CAGR) of -2.62%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $5.04 billion in 2023 at a CAGR of 7.01%. North America was the largest region in the anti-Parkinson drugs market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The increasing geriatric population and surging cases of Parkinson`s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 years. According to the United Nations Department of Economic and Social Affairs, one in 11 people in the world was over the age of 65 in 2019 and this number is expected to increase to one in six people by the end of 2050. Furthermore, according to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, over 1 million Americans live with PD. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease is therefore driving the market growth. Increasing investments by governments and companies for Parkinson’s disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, according to the report published in 2018 by the Parkinson’s Foundation, the foundation awarded $6 million to Parkinson`s disease (PD) research. In January 2019, Parkinson’s UK Research and Support charity in the United Kingdom announced a research investment of $1.9 million (£1.5 million) into its drug discovery program to develop novel gene transcription modulators for Parkinson’s disease. Hence, increasing investments in Parkinson’s drug development are expected to drive the anti-Parkinson`s drugs market. The high cost of Parkinson’s disease treatment is anticipated to limit the growth of anti-Parkinson`s drugs market over the forecast period. According to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, the economic burden of Parkinson’s disease on patients, families, and the federal governments is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson`s disease treatment is expected to impact the anti-Parkinson drugs market. In June 2019, AbbVie Inc., a global research-driven biopharmaceutical company, announced the acquisition of Allergan plc, a Dublin-based pharmaceutical company, for an amount of $63 billion. With Allergan’s diversified product portfolio, AbbVie Inc.is expected to strengthen the company’s position in international biopharmaceutical markets. AbbVie Inc. invested in neuroscience, multiple sclerosis, Alzheimer’s disease, and investigating potential disease for Parkinson’s disease. Allergan plc is a pharmaceutical company engaged in developing, manufacturing, and commercializing branded pharmaceutical, biologic, surgical, device, and regenerative medicine products for patients worldwide. The global anti-parkinson drugs market is segmented - 1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs. 2) By Route of Administration: Oral, Injection, Transdermal. 3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies.

The cancer clinical decision tools market consists of sales of cancer decision support tools and related services. Cancer decision tools are designed to support the general practitioner`s assessment of patients with potential cancer symptoms. The tools do not change the clinical judgment but give more information that is used to inform patient management decisions. The risk is measured based on reading coded information from the patient record including demographic data, medical history, and symptoms. The global cancer clinical decision tools market is expected to decline from $0.38 billion in 2019 to $0.35 billion in 2020 at a compound annual growth rate (CAGR) of -7.41%. The decline is mainly due to the COVID-19 outbreak that has deferred treatment for cancer unless the conditions are serious. The market is then expected to recover and reach $0.47 billion in 2023 at a CAGR of 10.23%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision tools market. According to the National Cancer Institute, the rate of incidence based on cases between 2013–2017 cases is 442.4 per 100,000 men and women per year. According to the American Cancer Society, there were 1.7 million new cases and 0.6 cancer deaths in 2019 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates across the globe will increase the demand for cancer clinical decision tools to make treatment decisions faster, thereby contributing to the market growth. The breach of data and privacy of patients is a major challenge in the cancer clinical decision tools market. Hackers can get access to data centers through healthcare employee’s emails leading to a breach of patients information privacy. For instance, in 2019, the Regional Cancer Care Association (RCCA) reported a data breach through phishing email attempts. Email phishing is a primary attack because it is not detectable by email security tools. Similarly, in 2018, out of 15 million patient records breached, 11.4 million records were caused by phishing attacks. The risk of the loss of data and privacy of patients harms the growth of the cancer clinical decision tools market. In January 2018, Elsevier, a Netherlands-based information analytics company specialized in science and health, acquired Via Oncology for an undisclosed amount. The acquisition is expected to accelerate Elsevier`s ability to support not only the referential needs of caregivers but also the workflow needs of clinicians. Integrating the decision tools in electronic medical records will help healthcare professionals to make informed decisions. Via Oncology is a Pennsylvania-based company that provides decision support in cancer care management. The global cancer clinical decision tools market is segmented - 1) By Type: Risk Assessment Tool(RAT), Qcancer. 2) By End-User: Hospital, Clinics.

The clinical nutrition market consists of sales of clinical nutrition interventions and related services by entities (organizations, sole traders and partnerships) that produce nutritional products that are used in the treatment of diseases related to malnutrition, restoring body tissue, and boosting energy and immunity in the body. Clinical nutrition helps in keeping the patient healthy by providing the required amount of nutrients such as proteins, vitamins, and minerals. The global clinical nutrition market is expected to grow from $38.19 billion in 2019 to $42.86 billion in 2020 at a compound annual growth rate (CAGR) of 12.23%. The growth is mainly due to the COVID-19 outbreak. Nutritional care is believed to influence recovery time and the patient’s ability to return to normal. Nutrition is vital in maintaining avoiding metabolic disturbances during the patient`s stay (around two weeks) in the intensive care. Also, as respiratory difficulties prevent patients from eating effectively, nutritional intake is important. The market is then expected to stabilize and reach $52.76 billion in 2023 at a CAGR of 7.18%. North America was the largest region in the clinical nutrition market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The rising geriatric population is anticipated to boost the growth of the clinical nutrition market. The clinical nutrition needs of elderly people are determined by several factors including specific health conditions and associated impairment of the organ system, the level of activity, energy consumption and caloric requirements of an individual, the capacity to access, prepare, consume and digest food, and personal dietary preferences. According to World Population Prospects 2019 (United Nations, 2019), one in 11 people was over the age of 65 and this number is expected to increase to one in six people by 2050, globally. Clinical nutrition problems in the elderly are related not only to multiple drug use but also to the consumption of specialized diets for one or more chronic illnesses. Thus, the growing geriatric population is anticipated to drive the market growth. Stringent government regulations are expected to hamper the growth of the clinical nutrition market. The increasing use of dietary products raised public health concerns about their efficacy and safety in both short and long terms. The most frequent concerns with nutritional products include intentional adulteration, contamination, and incorrect reporting on the claimed content by the manufacturers, which may lead to serious health hazards. To ensure public health safety, strict regulations have been initiated by major international and national bodies. Manufacturers are responsible to give appropriate label information, composition and use of products, and ensure the safety of their products under the intended conditions of use, as required by the authorities such as Central Drugs Standard Control Organisation (CDSCO) in India, European Medicines Agency (EMA) in Europe, and Food and Drug Administration (FDA) in the United States. Manufacturers must follow cGMPs with registration and periodic inspection of facilities and mandatory adverse event reporting. These stringent government regulations are limiting the overall growth of the clinical nutrition market. Major players operating in the industry are undergoing strategic initiatives such as increasing production capacity and expanding global presence. For instance, in May 2020, ESI Nutrition, a division of the dairy cooperative Laita, announced a new production line that is fully operational at the Ploudaniel`s facility and is the first commercial plant. ESI Nutrition also wanted to expand the range of formats available to its customers and released two new bottle sizes: 70ml and 90ml, smaller than the existing options. The new bottles are compact and perfect for ESI Nutrition’s flagship product “nourettes”, which are liquid infant formula pre-packaged in ready-to-use baby bottles with a dedicated screw top and adapted teat, handed out in maternity wards. These are designed ergonomically to be easier to manage and are also transparent, to keep a track of the consumption level. In February 2020, Kerry Group, an Ireland-based food and nutrition company, announced the acquisition of the plant-based protein company Pevesa Biotech for an undisclosed amount. The acquisition is intended to enhance Kerry’s position for specialized nutrition in the hydrolyzed plant protein space and expand the company`s capacity to serve the rapidly growing organic plant protein market. Pesava Biotech is a Spanish biotechnology company that specializes in non-GMO, general, non-allergic, and clinical nutrition products. The global clinical nutrition market is segmented - 1) By Product: Infant Nutrition, Parental Nutrition, Enteral Nutrition. 2) By Route of Administration: Oral, Enteral, Parenteral. 3) By Application: Cancer, Neurological Diseases, Gastrointestinal Disorders, Metabolic Disorders, Others. 4) By End User: Pediatric, Adults, Geriatric.

The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy. The global Granulocyte-Colony Stimulating Factor (G-CSF) is expected to decline from $7.30 billion in 2019 to $6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $8.33 billion in 2023 at a CAGR of 6.44%. North America was the largest region in the G-CSF market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the World Health Organization (WHO), 9.6 million deaths occurred in 2018 due to cancer. About 70% of deaths from cancer occur in low- and middle-income countries. G-CSF is a class of growth factor which produces white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market. The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the granulocyte-colony stimulating factor market. The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in instant medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57 % increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the costs of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market. In June 2019, Pfizer Inc., a US-based pharmaceutical corporation, acquired Array BioPharma Inc. for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. This acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory, particularly in the long term. Array BioPharma Inc, a US-based company, is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The global g-csf (granulocyte colony Stimulating factors) market is segmented - 1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex). 2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others.

The immunosuppressant market consists of sales of immunosuppressants or anti-rejection drugs generated by companies manufacturing immunosuppressant drugs. Immunosuppressants are medicinal substances that prevent or inhibit activity in the immune system. Immunosuppressive drugs are mainly used in organ transplantation procedures and also in the treatment of certain autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and others. The global immunosuppressants market is expected to grow from $14.9 billion in 2019 to $15.08 billion in 2020 at a compound annual growth rate (CAGR) of 1.21%. The slow growth is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $21.44 billion in 2023 at a CAGR of 12.45%. North America was the largest region in the immunosuppressants market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The surge in organ transplant procedures such as kidney transplant and liver transplant due to the rise in incidences of organ failure is the major factor driving the immunosuppressant market growth. According to the United Network for Organ Sharing (UNOS), 39,718 organ transplants were performed in 2019 in the United States, and as of March 2020, there are more than 112,000 candidates on the U.S. national transplant waiting list, waiting for an organ transplant. According to the Global Liver Institute’s 2019 report, there are 13,192 liver patients in the U.S. waiting for a lifesaving transplant. The increasing number of cases of organ transplants and organ failure incidences in patients are, therefore, expected to drive the market growth. Stringent government regulations are expected to hamper the growth of the market. Regulators such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) maintain public safety for food and drugs through a stringent regulatory drug approval process. For an immunosuppressant drug to be approved by the regulatory authorities, the sponsor must provide satisfactory evidence regarding the safety and efficacy of a drug in a patient with a defined clinical condition. Sponsors should submit to the Center for Drug Evaluation and Research (CDER) any information on the immunotoxicology evaluation of drugs whenever such information becomes available, for review. Many guidelines have also been adopted by the EU including those providing general guidance, more specific guidance on quality issues, and non-clinical and clinical aspects (for instance, 2001/83/EC). Therefore, the stringent regulatory and approval process on immunosuppressant drugs are projected to hamper the overall growth of the immunosuppressants market. The phenotypic personalized medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcome the issues with immunosuppressants. For instance, Tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation. When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently. PPM approach that is based on a computational platform is used to overcome this concern. The inputs from the computational platform-based PPM approach includes the past response of the patient to the dose of the drug and other drugs that are being taken, and current data on liver and kidney. Using PPM, the physician can identify the optimal drug and dose combination from various possibilities. Therefore, it is believed that artificial intelligence is leading the way to not only more personalized and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses. In 2019, AbbVie, an American publicly-traded biopharmaceutical company, acquired Allergan for $63 billion. The transaction significantly expanded and diversified AbbVie`s revenue base and existing leadership position in immunology with humira and recently launched skyrizi and rinvoq, and hematologic oncology with imbruvica and venclexta. Allergan provides new growth opportunities in neuroscience, with Botox therapeutics, Vraylar, and Ubrelvy and a global aesthetics business, with leading brands including Botox and Juvéderm. Allergan is an Irish-domiciled pharmaceutical company that develops, manufactures, and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The global immunosuppressants market is segmented - 1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others. 2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases. 3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies.

The inhalation sedatives market consists of sales of inhalation sedatives by companies who manufacture them. Inhalation sedatives are the drugs used to induce or maintain inhalation sedation, which is a type of conscious sedation where a drug is inhaled to suppress the central nervous system activity so that there is no much stress on the patient during a surgical process or a treatment and responds to the physician commands without protective reflexes. Inhalation sedatives are used in hospitals, ambulatory surgical centers and other care providing centers. The global inhalation sedatives market is expected to increase from $1.27 billion in 2019 to $1.29 billion in 2020 at a compound annual growth rate (CAGR) of 1.2%. The growth is mainly due to the COVID-19 outbreak. The infected individuals with severe ARDS require sedation most frequently, and inhalation sedatives are being increasingly considered as they are associated with rapid onset of inhalation and effective outcomes. Inhaled sedatives can reduce lung inflammation, shorten the duration of ventilation and potentially improve survival. The market is then expected to stabilize and reach $1.48 billion in 2023 at a CAGR of 4.8%. North America was the largest region in the inhalation sedatives market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The short onset and duration time of inhalation sedative is expected to drive the inhalation sedative market. Rapid onset of inhalation sedative and quick recovery rate makes it applicable for short procedures especially in dental surgeries of paediatrics, and in intensive care units for decreasing the pain and quick recovery. For instance, the most commonly used inhaled sedative is nitrous oxide, which is administered as a mixture of 30-70% of oxygen, takes about 1-2 minutes to act and the duration of action is 5 minutes. The short time required for the onset of action and its short duration makes nitrous oxide the most used inhalation sedative for dental treatment. Therefore, the short onset and duration time of inhalation sedatives is expected to drive the inhalation sedatives market. Contradictions associated with inhalation sedatives are expected to hinder the market. Inhalation sedatives, although safe most of the time, can rarely result in adverse events. For instance, inhalation sedatives cannot be used in patients who have undergone a recent ear surgery as they build up pressure in the middle ear. Also, in pregnant women, the use of inhalation sedatives is avoided to minimize the risk of possible toxicity. Inhalation sedatives affect the foetus by interfering with folic acid absorption in pregnant ladies causing neurotoxicity. Studies show that prolonged exposure to nitrous oxide may cause reproductive and haematological disorders in the operator. The inhalation sedatives also cannot be used for patients with common cold, nasal blockage, or COPD as they cannot be absorbed by the patient, and therefore do not show the required effect. All these factors are causing a hindrance to the usage of inhalation sedatives and an acceptance of other sedative methods. Therefore, contraindications associated with inhalation sedatives are expected to hinder the market. The production of generic inhalation sedatives is expected to be the new trend in the inhalation sedatives market. Generics are a type of drug that has the same chemical formula, dosage form, dose and effect as that of the patented drug but are produced by the companies when the patent expires. The generic inhalation sedatives production has increased for the last few years. For instance, in January 2019, Novartis’ division Sandoz has launched a liquid for inhalation called desflurane in the United States, a first generic of an inhalation agent suprane that is used for induction and maintenance in adults and paediatrics. Health Canada has given a receipt of a drug identification number to Blue-Zone Technologies Ltd that permits it to launch the generic desflurane drug. Therefore, the production of generic inhalation sedatives is expected to become the new trend in the inhalation sedatives market The global inhalation sedatives market is segmented - 1) By Product: Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide. 2) By Application: Induction, Maintenance. 3) By End-User: Hospitals, Ambulatory Surgical Centers, Others.